These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 31830095)
41. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK; MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060 [TBL] [Abstract][Full Text] [Related]
42. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. Asfaw A; Ali D; Eticha T; Alemayehu A; Alemayehu M; Kindeya F PLoS One; 2015; 10(3):e0122583. PubMed ID: 25816222 [TBL] [Abstract][Full Text] [Related]
43. Multi-state Markov model for time to treatment changes for HIV/AIDS patients: a retrospective cohort national datasets, Ethiopia. Kumsa TH; Mulu A; Beyene J; Asfaw ZG BMC Infect Dis; 2024 Jun; 24(1):627. PubMed ID: 38914968 [TBL] [Abstract][Full Text] [Related]
44. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030 [TBL] [Abstract][Full Text] [Related]
45. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028 [TBL] [Abstract][Full Text] [Related]
46. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544 [TBL] [Abstract][Full Text] [Related]
47. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D; Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715 [TBL] [Abstract][Full Text] [Related]
49. Immunological Response of Hiv-Infected Children to Highly Active Antiretoviral Therapy at Gondar University Hospital, North-Western Ethiopia. Kokeb M; Degu G Ethiop J Health Sci; 2016 Jan; 26(1):25-30. PubMed ID: 26949313 [TBL] [Abstract][Full Text] [Related]
50. HIV-associated anaemia before and after initiation of antiretroviral therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia. Adane A; Desta K; Bezabih A; Gashaye A; Kassa D Ethiop Med J; 2012 Jan; 50(1):13-21. PubMed ID: 22519158 [TBL] [Abstract][Full Text] [Related]
51. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932 [TBL] [Abstract][Full Text] [Related]
52. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. Mulu A; Maier M; Liebert UG PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902 [TBL] [Abstract][Full Text] [Related]
53. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. Hill A; Sawyer W HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663 [TBL] [Abstract][Full Text] [Related]
54. HIV treatment outcomes following antiretroviral therapy initiation and monitoring: A workplace program in Papua, Indonesia. Limmade Y; Fransisca L; Rodriguez-Fernandez R; Bangs MJ; Rothe C PLoS One; 2019; 14(2):e0212432. PubMed ID: 30802257 [TBL] [Abstract][Full Text] [Related]
55. Immunologic and Clinical Failure of Antiretroviral Therapy in People Living with Human Immunodeficiency Virus within Two Years of Treatment. Asgedom SW; Maru M; Berihun B; Gidey K; Niriayo YL; Atey TM Biomed Res Int; 2020; 2020():5474103. PubMed ID: 32462003 [TBL] [Abstract][Full Text] [Related]
56. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
57. Viral load suppression and its predictor among HIV seropositive people who receive enhanced adherence counseling at public health institutions in Bahir Dar, Northwest Ethiopia. Retrospective follow-up study. Belete MB; Bitew A; Mulatu K PLoS One; 2024; 19(5):e0303243. PubMed ID: 38739646 [TBL] [Abstract][Full Text] [Related]
58. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study. Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106 [TBL] [Abstract][Full Text] [Related]
59. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604 [TBL] [Abstract][Full Text] [Related]
60. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B; HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]